Leucocyte cell-derived chemotaxin 2 related amyloidosis: Difference between revisions
Jump to navigation
Jump to search
Aditya Ganti (talk | contribs) |
Aditya Ganti (talk | contribs) |
||
| Line 32: | Line 32: | ||
<br /> | <br /> | ||
{{familytree/start}} | |||
{{familytree | | | | | | | | | A01 | | | | | |A01=A01}} | |||
{{familytree | | | | | | | | | |!| | | | | | | | }} | |||
{{familytree | | | | | | | | | B01 | | | | | |B01=B01}} | |||
{{familytree | | |,|-|-|-|-|-|-|+|-|-|-|-|-|-|.| }} | |||
{{familytree | | C01 | | | | | C02 | | | | | C03 |C01=C01|C02=C02|C03=C03}} | |||
{{familytree | | | | | | | | | |!| | | | | | | | }} | |||
{{familytree | |,|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|.| | }} | |||
{{familytree | |!| | | |!| | | |!| | | |!| | | |!| | | }} | |||
{{familytree | D01 | | D02 | | D03 | | D04 | | D05 |D01=D01|D02=D02|D03=D03|D04=D04|D05=D05}} | |||
{{familytree | |!| | | | | | | | | | | | | | | |!| }} | |||
{{familytree | E01 | | | | | | | | | | | | | | E02 |E01=E01|E02=E02}} | |||
{{familytree/end}} | |||
==Causes== | ==Causes== | ||
Revision as of 14:05, 30 October 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Synonyms and keywords:LECT2 amyloidosis
Overview
Historical Perspective
- The first case of ALECT2 was discovered by Benson et al in 2008.
Classification
Pathophysiology
- The pathogenesis of this disease is related to accumulation of a protein called LECT2.
- LECT2 protein is a multi functional factor involved in
- Chemotaxis
- Inflammation
- Immunomodulation
- Damage/repair process.
- LECT2 is synthesized mainly by hepatocytes but also expressed in many organs, including vascular endothelial cells, smooth muscle cells, adipocytes, and epithelial cells such as renal tubular epithelial cells.
- According to the literature, ALECT2 involves G/A polymorphism affecting nucleotide 172 in exon 3 of the LECT2 protein.
- Substitution of the isoleucine with valine at position 40 makes the protein unstable imparting an amyloidogenic property to the LECT2 protein.
- Alternately the disease could be due to interference in the LECT2 catabolic pathway or LECT2 transport.
- Possibly resulting from a genetic defect which ultimately results in an increased local tissue concentration of LECT2 leading to amyloid fibril formation.
- The kidney is the primary target of this disease. '
- Other common organs involved other than the kidney include liver, spleen, prostate, gastrointestinal tract, peripheral nervous system, and lungs.
- Cardiac involvement never occurs, which gives this disease a survival advantage compared to other forms of amyloidosis.
- Other organs which are not involved include brain, pancreas, and fibroadipose tissue.
| A01 | |||||||||||||||||||||||||||||||||||||||||
| B01 | |||||||||||||||||||||||||||||||||||||||||
| C01 | C02 | C03 | |||||||||||||||||||||||||||||||||||||||
| D01 | D02 | D03 | D04 | D05 | |||||||||||||||||||||||||||||||||||||
| E01 | E02 | ||||||||||||||||||||||||||||||||||||||||